Tradestie Institutional Equity Comparison Engine

HAE vs THOR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HAE Overall Edge

HAE Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Haemonetics Corporation (HAE) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, HAE trades at 22.7x Forward P/E with 18.8% operating margin (+9.3% YoY revenue) versus THOR at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, HAE sits in UNCLASSIFIED (2nd %ile IV; Dealer Gamma Walls on Pro) against THOR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner HAE
HAE 22.7x vs THOR N/M Fwd P/E
Growth & Margin Winner HAE
Op Margin 18.8% vs N/A ยท YoY +9.3% vs N/A
Momentum & Technical Winner HAE
1Y +59.8% vs -1.4% ยท 52W Pos 85% vs 2%
Options & Structure Winner HAE
UNCLASSIFIED (2nd %ile IV) vs UNCLASSIFIED (N/A IV)
HAE NYSE
Haemonetics Corporation
Surgical & Medical Instruments & Apparatus
$120.16
-0.17% 1D
Market Cap $5.5B
1M Return +3.44%
1Y Return +59.81%
Forward P/E 22.7x
Unified AI Score
49.2 / 100 HOLD
Tech 40.0 Fund 38.0 Flow 50.0 Mom 21.1
THOR US Equity
THOR
Institutional Equity
$24.63
-1.7% 1D
Market Cap N/A
1M Return -3.92%
1Y Return -1.43%
Forward P/E N/M
Unified AI Score
44.5 / 100 HOLD
Tech 27.0 Fund 50.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HAE +59.81% THOR -1.43% Spread: +66.53 pp (HAE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
HAE TTM Op. Margin: 18.8% THOR TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HAE vs THOR. Trailing 12-month operating profitability (HAE 18.8% vs THOR N/A) and valuation multiples (HAE 22.7x vs THOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HAE (9) vs THOR (1)
Institutional Metric HAE THOR Criterion Row Winner
Market Capitalization Scale $5.5B N/A Larger Scale HAE
Trailing P/E Ratio Valuation 53.3x N/M Lower Multiple HAE
Forward P/E Ratio Valuation 22.7x N/M Lower Multiple HAE
Revenue Growth (YoY) Growth +9.3% N/A Higher Growth HAE
Operating Margin (TTM) Profitability 18.8% N/A Higher Margin HAE
Net Profit Margin Profitability 7.5% N/A Higher Margin HAE
Return on Equity (ROE) Capital Efficiency 11.9% N/A Higher ROE HAE
52-Week Range Position Momentum 85% ($51โ€“$132) 2% ($25โ€“$29) Stronger Trend HAE
Beta / 30D Volatility Risk Regime 0.28ฮฒ ยท 33% Vol 0.46ฮฒ ยท 17% Vol Lower Realized Risk THOR
Unified Institutional Score Composite Signal 49.2 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite HAE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HAE vs THOR Buy Guide
HAE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live HAE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
THOR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live THOR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HAE nor THOR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.